Published in Lab Business Week, May 1st, 2005
The debentures may be converted in whole or in part by the holder at any time into common shares of the corporation at a price of $0.45 per common share and may be redeemed at any time by the corporation.
The proceeds from the debentures will be used primarily for the development of the corporation's SonoLight-based technology to proceed to clinical trials.
The foregoing transaction is subject to regulatory approval, including the approval of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.